Key Highlights
- Danish pharmaceutical company’s oral GLP-1 medication achieved its primary endpoint in a phase 3 study with young type 2 diabetes patients
- Participants experienced a 0.83 percentage point greater reduction in HbA1c levels compared to placebo across a 26-week period
- Study enrolled 132 participants ranging from 10 to 17 years old
- This would mark the first oral GLP-1 treatment authorized for pediatric populations
- Regulatory submissions anticipated in both American and European markets during late 2026
Novo Nordisk announced Thursday that its oral semaglutide medication successfully demonstrated blood glucose reduction capabilities in young patients diagnosed with type 2 diabetes, based on late-stage clinical trial data.
The 26-week study involved 132 participants aged between 10 and 17 years. Those receiving the active treatment experienced HbA1c reductions that exceeded placebo recipients by 0.83 percentage points.
The pharmaceutical manufacturer characterized these findings as statistically significant, confirming the study achieved its primary objective.
This represents a pioneering effort to evaluate an oral GLP-1 medication in pediatric and adolescent populations. To date, no oral GLP-1 treatment has received authorization for this demographic.
The medication currently reaches adult patients through the commercial names Rybelsus and Ozempic pill. Market availability of an Ozempic pill formulation in the United States is anticipated during Q2 2026.
Historically associated with adult patients, type 2 diabetes now affects a growing number of young people. Current CDC statistics indicate approximately 364,000 American children and teenagers under age 20 have received diabetes diagnoses.
Shortage of Therapeutic Alternatives for Younger Demographics
Physicians managing younger diabetes patients face limited pharmaceutical options. Metformin represents the conventional first-line therapy, yet it demonstrates inadequate glycemic control in approximately 50% of adolescent cases.
Insulin therapy serves as another primary alternative, though it presents concerns including hypoglycemic events and increased body weight. An oral medication with favorable tolerability would address a significant unmet medical need.
Martin Holst Lange, serving as Novo Nordisk’s chief scientific officer, noted the dramatic increase in type 2 diabetes prevalence among youth over recent decades.
“Oral semaglutide is an effective treatment option for children and adolescents with Type 2 diabetes who require glycaemic control beyond that provided by the current standard of care,” Lange said.
Regulatory Submission Timeline Set for Second Half of 2026
The Copenhagen-based company intends to pursue regulatory authorization for label expansion covering both Rybelsus and Ozempic pill to encompass pediatric and adolescent patients in American and European markets during H2 2026.
Approval would establish semaglutide as the inaugural oral GLP-1 therapy authorized for younger patients.
Trial safety data aligned with observations from previous semaglutide studies conducted in adult subjects.
Successful regulatory clearance would broaden Novo’s semaglutide product portfolio into an additional patient segment, potentially providing the Danish pharmaceutical company with competitive advantages over competitor Eli Lilly (LLY) within the diabetes and obesity treatment markets.
Novo Nordisk anticipates submitting regulatory applications in both jurisdictions prior to year-end.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
